Chargement en cours...
Trastuzumab Deruxtecan: Changing the Destiny of HER2 Expressing Solid Tumors
HER2 targeted therapies have significantly improved prognosis of HER2-positive breast and gastric cancer. HER2 overexpression and mutation is the pathogenic driver in non-small cell lung cancer (NSCLC) and colorectal cancer, however, to date, there are no approved HER2-targeted therapies with these...
Enregistré dans:
| Publié dans: | Int J Mol Sci |
|---|---|
| Auteurs principaux: | , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
MDPI
2021
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8125530/ https://ncbi.nlm.nih.gov/pubmed/33946310 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/ijms22094774 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|